ArticleJournal of clinical microbiology2006
Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 126 citations in OpenAlex.
- Genomic insights into one carbapenem-resistant and multidrug-resistantMicrobiology spectrum · 2026Article
- Characterization of phenotypic and genotypic traits of Klebsiella pneumoniae strains resistant to 3rd generation cephalosporins in hospital settings: A case study in Ho Chi Minh City, Vietnam.Molecular biology reports · 2025Article
- Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance.Nature communications · 2024Article
- Review
- Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.Microbiology spectrum · 2022Article
- Genomic Characterization of ESBL/AmpC-ProducingInfection and drug resistance · 2022Article
- Occurrence and plasmid profiles of multidrug-resistantBiotechnologia · 2021Article
- Monitoring of Non-β-Lactam Antibiotic Resistance-Associated Genes in ESBL ProducingAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Expression of a Shiga-Like Toxin during Plastic Colonization by Two Multidrug-Resistant Bacteria,Microorganisms · 2020Article
- Lineage, Antimicrobial Resistance and Virulence of Citrobacter spp.Pathogens (Basel, Switzerland) · 2020Article
- Genetics of Acquired Antibiotic Resistance Genes inFrontiers in microbiology · 2020Review
- Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2019Article
- Impact of InducibleAntimicrobial agents and chemotherapy · 2018Article
- Genetic Diversity, Multidrug Resistance, and Virulence ofFrontiers in cellular and infection microbiology · 2018Article
- Chromosomal Amplification of the blaOXA-58 Carbapenemase Gene in a Proteus mirabilis Clinical Isolate.Antimicrobial agents and chemotherapy · 2017Article
- Antimicrobial Resistance and Cytotoxicity ofFrontiers in microbiology · 2017Article
- Genetic environment of the KPC gene in Acinetobacter baumannii ST2 clone from Puerto Rico and genomic insights into its drug resistance.Journal of medical microbiology · 2016Article
- Appearance of β-lactam Resistance Genes in Agricultural Soils and Clinical Isolates over the 20th Century.Scientific reports · 2016Article
- Comparison of the Carba NP, Modified Carba NP, and Updated Rosco Neo-Rapid Carb Kit Tests for Carbapenemase Detection.Journal of clinical microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newer beta-lactamases such as extended-spectrum beta-lactamases (ESBLs), transferable AmpC beta-lactamases, and carbapenemases are associated with laboratory testing problems of false susceptibility that can lead to inappropriate therapy for infected patients. Because there appears to be a lack of awareness of these enzymes, a study was conducted during 2001 to 2002 in which 6,421 consecutive, nonduplicate clinical isolates of aerobically growing gram-negative bacilli from patients at 42 intensive care unit (ICU) and 21 non-ICU sites across the United States were tested on-site for antibiotic susceptibility. From these isolates, 746 screen-positive isolates (11.6%) were referred to a research facility and investigated to determine the prevalence of ESBLs in all gram-negative isolates, transferable AmpC beta-lactamases in Klebsiella pneumoniae, and carbapenemases in Enterobacteriaceae. The investigations involved phenotypic tests, isoelectric focusing, beta-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular analyses. ESBLs were detected only in Enterobacteriaceae (4.9% of all Enterobacteriaceae) and were found in species other than those currently recommended for ESBL testing by the CLSI (formerly NCCLS). These isolates occurred at 74% of the ICU sites and 43% of the non-ICU sites. Transferable AmpC beta-lactamases were detected in 3.3% of K. pneumoniae isolates and at 16 of the 63 sites (25%) with no difference between ICU and non-ICU sites. Three sites submitted isolates that produced class A carbapenemases. No class B or D carbapenemases were detected. In conclusion, organisms producing ESBLs and transferable AmpC beta-lactamases were widespread. Clinical laboratories must be able to detect important beta-lactamases to ensure optimal patient care and infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.